Randy Sabett

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.

Cooley advised the underwriters of Caris Life Sciences, a patient-centric, next-generation artificial intelligence techbio company and precision medicine pioneer, in connection with Caris’ $494 million initial public offering (IPO).

Cooley advised Blue Owl Capital (NYSE: OWL), an asset manager redefining alternatives, on an up to $262.5 million term loan facility for ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors.

Cooley advised the underwriters of Aardvark Therapeutics, a phase 3 biotech company developing novel small-molecule therapies for metabolic diseases, in connection with Aardvark’s $94.2 million initial public offering (IPO).

Cooley advised SiteOne Therapeutics, a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough and other conditions, on its $100 million Series C financing.